Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. MedSci Healthcare Holdings's Research & Development for the
six
months ended in Dec. 2025 was HK$12.1 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$33.6 Mil.
MedSci Healthcare Holdings (HKSE:02415) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
MedSci Healthcare Holdings Research & Development Related Terms
MedSci Healthcare Holdings Research & Development Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedSci Healthcare Holdings Research & Development Chart
MedSci Healthcare Holdings Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$33.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of HK$33.6 Mil mean?
MedSci Healthcare Holdings (HKSE:02415) has a Research & Development of HK$33.6 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on MedSci Healthcare Holdings and its competitors.
Is MedSci Healthcare Holdings' Research & Development too high?
MedSci Healthcare Holdings' current Research & Development is HK$33.6 Mil. Overall, MedSci Healthcare Holdings has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MedSci Healthcare Holdings' Research & Development compare to VEEV and BTSG?
MedSci Healthcare Holdings' Research & Development of HK$33.6 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MedSci Healthcare Holdings and its competitors. MedSci Healthcare Holdings's current Research & Development is HK$33.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedSci Healthcare Holdings stock overvalued right now?
Based on GuruFocus' analysis, MedSci Healthcare Holdings (HKSE:02415) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.44, compared to a current price of HK$0.73 — trading 49.3% below its estimated fair value. The current Research & Development is HK$33.6 Mil. MedSci Healthcare Holdings' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MedSci Healthcare Holdings (HKSE:02415), the current Research & Development is HK$33.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedSci Healthcare Holdings (HKSE:02415) Overvalued in 2026?
Based on GuruFocus' analysis, MedSci Healthcare Holdings stock appears to be undervalued.
The current stock price of HK$0.73 is trading 49.3% below its estimated GF Value™ of HK$1.44.
GuruFocus considers MedSci Healthcare Holdings to be Possible Value Trap.
Key valuation signals for HKSE:02415:
Research & Development: HK$33.6 Mil
GF Value™: HK$1.44 vs. price of HK$0.73 (49.3% below fair value)
No single metric tells the full story. See the HKSE:02415 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedSci Healthcare Holdings Ltd is an investment holding company. It operates online professional physician platforms in China. The principal activities of the company are the provision of physician platform solutions, precision omni-channel marketing solutions, and real-world study solutions in the People's Republic of China.
79GF Score
Get the complete analysis for HKSE:02415
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02415 has been successfully added to your 
